AstraZeneca shares positive interim results from phase 3 lymphoma trial
Betsy Goodfellow | May 3, 2024 | News story | Medical Communications | AstraZeneca, Calquence, Oncology, clinical trial, lymphoma
AstraZeneca has announced positive high-level results from an interim analysis of the ECHO phase 3 trial, which assessed Calquence (acalabrutinib) in combination with standard-of-care chemoimmunotherapy, bendamustine and rituximab, for the treatment of mantle cell lymphoma (MCL).
The trial demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared to standard of care in previously untreated adult patients with MCL.
The trial also showed a trend in favour of Calquence with chemoimmunotherapy for the secondary endpoint of overall survival (OS), however the full OS data was not mature at this stage so the trial is intended to continue to assess this endpoint.
The safety and tolerability of the drug was consistent with its known safety profile, with no new safety signals being observed.
This data is expected to be presented at an upcoming medical meeting as well as being supplied to the relevant global regulatory authorities.
Susan Galbraith, executive vice president of oncology R&D at AstraZeneca, commented: “These impactful results in mantle cell lymphoma show that bringing Calquence to the first-line setting significantly delays disease progression and, for the first time, shows potential to extend survival. The improvement in progression-free survival together with the differentiated safety profile of Calquence are both important as we strive to transform outcomes earlier in the course of disease treatment.”
Betsy Goodfellow
Related Content
UCB announces first-in-patient trial success for galvokimig in atopic dermatitis
UCB has reported positive early clinical trial results for galvokimig, an investigational therapy for adults …
FDA approves Wegovy for treatment of MASH in adults with liver fibrosis
The US Food and Drug Administration (FDA) has granted accelerated approval for Wegovy (semaglutide) as …
HUTCHMED completes enrolment in phase 3 trial for lung cancer
HUTCHMED has completed patient enrolment for the SANOVO phase 3 clinical trial, investigating the use …
